Panavance Therapeutics
Our Science
Pipeline
About GP-2250
About
About Panavance
Leadership
Board of Directors
Advisors & Collaborators
Contact Panavance
Resources
Publications
Brochures
Videos
Press Releases
Events
Participate
Let’s engage
.
An In Vitro Pilot Study Investigating the Antineoplastic Effects of GP-2250 on Cutaneous Squamous Cell Carcinoma Cell Lines: Preliminary Results
December 10, 2023
/
0 Minute Read